Endothelial-derived hyperpolarization factor (EDHF) contributes to PlGF-induced dilation of mesenteric resistance arteries from pregnant rats

Journal of Vascular Research

Volumn 49, Issue 1, 2011, Pages 43-49

  Mandalà, Maurizio ^a,b   Gokina, Natalia ^a   Barron, Carolyn ^a   Osol, George ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF CALABRIA   (Italy)

Author keywords

Endothelial derived hyperpolarization factor; Mesenteric artery; PlGF; Potassium channels

Indexed keywords

APAMIN; CALCIUM; CHARYBDOTOXIN; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; IBERIOTOXIN; INDOMETACIN; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; POTASSIUM CHANNEL; PROSTAGLANDIN SYNTHASE INHIBITOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HYPERPOLARIZATION; HYPERTENSION; MESENTERIC ARTERY; NONHUMAN; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; RAT; RESISTANCE BLOOD VESSEL; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ACETYLCHOLINE; ANIMALS; APAMIN; BIOLOGICAL FACTORS; CALCIUM; CHARYBDOTOXIN; FEMALE; MESENTERIC ARTERIES; NG-NITROARGININE METHYL ESTER; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASODILATION;

EID: 80053497768     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000329821     Document Type: Article

References (41)

1. Molvarec A, Szarka A, Walentin S, Szucs E, Nagy B, Rigo J Jr: Circulating angiogenic factors determined by electrochemiluminescence immunoassay in relation to the clinical features and laboratory parameters in women with pre-eclampsia. Hypertens Res 2010; 33: 892-898.
2. Jeevaratnam K, Nadarajah VD, Judson JP, Nalliah S, Abdullah MF: Periodic assessment of Plasma sFlt-1 and PlGF concentrations and its association with placental morphometry in gestational hypertension (GH) -a prospective follow-up study. BMC Pregnancy Childbirth 2010; 10: 58.
3. Woods AK, Hoffmann DS, Weydert CJ, Butler SD, Zhou Y, Sharma RV, Davisson RL: Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension 2011; 57: 94-102.
4. Brownbill P, Mills TA, Soydemir DF, Sibley CP: Vasoactivity to and endogenous release of vascular endothelial growth factor in the in vitro perfused human Placental lobule from Pregnancies complicated by preeclampsia. Placenta 2008; 29: 950-955.
5. Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH: Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol 2008; 32: 871-876.
6. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelail dysfunction, hypertension, and protenuria in preeclampsia. J Clin Invest 2003; 111: 649-658. (Pubitemid 36278583)
7. Szukiewicz D, Szewczyk G, Watroba M, Kurowska E, Maslinski S: Isolated placental vessel response to vascular endothelial growth factor and placental growth factor in normal and growth-restricted pregnancy. Gynecol Obstet Invest 2005; 59: 102-107. (Pubitemid 40868079)
8. Wei W, Jin H, Chen ZW, Zioncheck TF, Yim AP, He GW: Vascular endothelial growth factor-induced nitric oxide-and PGI2-dependent relaxation in human internal mammary arteries: A comparative study with KDR and Flt-1 selective mutants. J Cardiovasc Pharmacol 2004; 44: 615-621. (Pubitemid 39441704)
9. Janvier A, Nadeau S, Baribeau J, Perreault T: Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung. Crit Care Med 2005; 33: 860-866.
10. Parenti A, Brogelli L, Filippi S, Donnini S, Ledda F: Effect of hypoxia and endothelial loss on vascular smooth muscle cell responsiveness to VEGF-A: role of flt-1/VEGF-receptor-1. Cardiovasc Res 2002; 55: 201-212. (Pubitemid 34615954)
11. Osol G, Celia G, Gokina N, Barron C, Chien E, Mandala M, Liksha L, Kublickiene K: Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol 2008; 294:H1381-H1387. (Pubitemid 351468737)
12. Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450. (Pubitemid 15114340)
13. Knot HJ, Nelson MT: Regulation of arterial diameter and wall [Ca 2+ ] in cerebral arteries of rat by membrane potential and intravascular pressure. J Physiol (Lond) 1998; 508: 199-209. (Pubitemid 28167582)
14. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9-22. (Pubitemid 29038270)
15. Grummer MA, Sullivan JA, Magness RR, Bird IM: VEGF acts through novel, pregnancy-enhanced receptor signaling pathways to stimulate endothelial nitric oxide synthase activity in uterine artery endothelial cells. Biochem J 2009; 417: 501-511.
16. Brownbill P, McKeeman GC, Brockelsby JC, Crocker IP, Sibley CP: Vasoactive and permeability effects of vascular endothelial growth factor-165 in the term in vitro dually perfused human placental lobule. Endocrinology 2007; 148: 4734-4744. (Pubitemid 47481518)
17. Park JE, Chen HH, Winer J, Houck KA, Ferrara N: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994; 269: 25646-25654.
18. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R: Neutralization of circulating VEGF by anti-VEGF antibodies and sFlt-1 induces proteinuria. J Biol Chem 2003; 278: 12605-12608.
19. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683. (Pubitemid 38364626)
20. Osol G, Barron C, Gokina N, Mandala M: Inhibition of nitric oxide synthases abrogates pregnancy-induced uterine vascular expansive remodeling. J Vasc Res 2009; 46: 478-486.
21. Lyall F, Greer IA, Boswell F, Fleming R: Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 1997; 104: 223-228. (Pubitemid 27065149)
22. Molvarec A, Ito M, Shima T, Yoneda S, Toldi G, Stenczer B, Vásárhelyi B, Rigó J Jr, Saito S: Decreased proportion of peripheral blood vascular endothelial growth factor-expressing T and natural killer cells in preeclampsia. Am J Obstet Gynaecol 2010; 203: 567.e1-e8.
23. Burger NZ, Kuzina OY, Osol G, Gokina NI: Estrogen replacement enhances EDHF-mediated vasodilation of mesenteric and uterine resistance arteries: role of endothelial cell Ca 2+ . Am J Physiol Endocrinol Metab 2009; 296:E503-E512.
24. Kenny LC, Baker PN, Kendall DA, Randall MD, Dunn WR: Differential mechanisms of endothelium-dependent vasodilator responses in human myometrial small arteries in normal pregnancy and pre-eclampsia. Cli Sci (lond) 2002; 103: 67-73. (Pubitemid 34729126)
25. Gokina NI, Kuzina OY, Vance AM: Augmented EDHF signaling in rat uteroplacental vasculature during late pregnancy. Am J Physiol 2010; 299:H1642-H1652.
26. Gerber RT, Anwar MA, Poston L: Enhanced acetylcholine induced relaxation in small mesenteric arteries from pregnant rats: an important role for endothelium-derived hyperpolarizing factor (EDHF). Br J Pharmacol 1998; 125: 455-460. (Pubitemid 28451482)
27. Luksha L, Agewall S, Kublickiene K: Endothelium-derived hyperpolarizing factor in vascular physiology and cardiovascular disease. Atherosclerosis 2009; 202: 330-344.
28. Benedito S, Prieto D, Nielsen PJ, Nyborg NC: Histamine induces endothelium-dependent relaxation of bovine retinal arteries. Invest Ophthalm Vis Sci 1991; 32: 32-38.
29. Rahimi N: VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front Biosci 2006; 11: 818-829. (Pubitemid 43262905)
30. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D, Kroll J, Plaisance S, De Mol M, bono F, Kliche S, Fellbrich G, Ballmerhofer K, Maglione D, Mayr-Beyrle U, Dewerchin M, Dombrowski S, Stanimirovic D, Van Hummelen P, Dehio C, Hicklin DJ, Persico G, Herbert JM, Communi D, Shibuya M, Collen D, Conway EM, Carmeliet P: Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-943. (Pubitemid 36889938)
31. Hecker M, Bara AT, Bauersachs J, Busse R: Characterization of EDHF as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol 1994; 481: 407-414.
32. Sandow SL, Tare M, Coleman HA, Hill CE, Parkington HC: Involvement of myoendothelial gap junctions in the actions of endothelium-derived hyperpolarizing factor. Circ Res 2002; 90: 1108-1113. (Pubitemid 34627910)
33. Edward G, Dora KA, Gardener MJ, Garland CJ, Weston AH: K + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396: 269-272. (Pubitemid 28541391)
34. McNeish AJ, Nelli S, Wilson WS, Dowell FJ, Martin W: Differential effects of ascorbate on EDHF-mediated vasodilation in the bovine ciliary vascular bed and coronary artery. Br J Pharmacol 2003; 138: 1172-1180. (Pubitemid 36459840)
35. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH: EDHF: bringing the concepts together. Trends Pharmacol Sci 2002; 23: 374-380.
36. Feletou M, Vanhoutte PM: EDHF: an update. Clin Sci (Lond) 2009; 117: 139-155.
37. Grgic I, Kaistha BP, Hoyer J, Kohler R: Endothelial Ca 2+-activated K + channels in normal and impaired EDHF-dilator responses-relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol 2009; 157: 509-526.
38. Jackson W: Potassium channels in the peripheral microcirculation. Microcirculation 2005; 12: 113-127. (Pubitemid 40450623)
39. Feletou M: Calcium-activated potassium channels and endothelial dysfunction: therapeutic options Br J Pharmacol 2009; 156: 545-562.
40. Meyer RD, Rahimi N: Comparative structure-function analysis of VEGFR-1 and VEGFR-2: What have we learned from chimeric systems Ann NY Acad Sci 2003; 995: 200-207. (Pubitemid 36706627)
41. Cunningham SA, Tran TM, Arrate MP, Bjercke R, Brock TA: KDR activation is crucial for VEGF165-mediated Ca 2+ mobilization in human umbilical vein endothelial cells. Am J Physiol 1999; 276:C176-C181. (Pubitemid 29063580)